Australia markets closed

Sumitomo Pharma Co., Ltd. (DNPUF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
4.50000.0000 (0.00%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.62B
Enterprise value 4.32B
Trailing P/E N/A
Forward P/E 15.22
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.77
Price/book (mrq)1.63
Enterprise value/revenue 1.86
Enterprise value/EBITDA -0.03

Trading information

Stock price history

Beta (5Y monthly) 0.61
52-week change 325.35%
S&P500 52-week change 326.33%
52-week high 34.5000
52-week low 31.9900
50-day moving average 33.2806
200-day moving average 32.7809

Share statistics

Avg vol (3-month) 3187
Avg vol (10-day) 3N/A
Shares outstanding 5397.29M
Implied shares outstanding 6407.57M
Float 8169.56M
% held by insiders 157.71%
% held by institutions 116.47%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.1
Forward annual dividend yield 44.05%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 3�
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 430 Mar 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin -78.95%
Operating margin (ttm)-3.42%

Management effectiveness

Return on assets (ttm)-19.08%
Return on equity (ttm)-90.02%

Income statement

Revenue (ttm)329.55B
Revenue per share (ttm)829.48
Quarterly revenue growth (yoy)19.80%
Gross profit (ttm)N/A
EBITDA -271.22B
Net income avi to common (ttm)-260.17B
Diluted EPS (ttm)-4.5900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)78.4B
Total cash per share (mrq)197.33
Total debt (mrq)390.07B
Total debt/equity (mrq)242.39%
Current ratio (mrq)0.65
Book value per share (mrq)404.89

Cash flow statement

Operating cash flow (ttm)-136.79B
Levered free cash flow (ttm)-190.18B